{
    "root": "645ea9e5-c2f5-40ef-85cd-3c1b5d8d0f27",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Diprivan"
    },
    "value": "20250421",
    "ingredients": [
        {
            "name": "PROPOFOL",
            "code": "YI7VU623SF"
        },
        {
            "name": "SOYBEAN OIL",
            "code": "241ATL177A"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "EGG PHOSPHOLIPIDS",
            "code": "1Z74184RGV"
        },
        {
            "name": "EDETATE DISODIUM ANHYDROUS",
            "code": "8NLQ36F6MM"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        }
    ],
    "indications": "DIPRIVAN is an intravenous general anesthetic and sedation drug indicated for: \n                  \n                     \n                        •Induction of General Anesthesia for Patients Greater than or Equal to 3 Years of Age\n                     \n                        •Maintenance of General Anesthesia for Patients Greater than or Equal to 2 Months of Age\n                     \n                        •Initiation and Maintenance of Monitored Anesthesia Care (MAC) Sedation in Adult Patients\n                     \n                        •Sedation for Adult Patients in Combination with Regional Anesthesia\n                     \n                        •Intensive Care Unit (ICU) Sedation of Intubated, Mechanically Ventilated Adult Patients\n                  \n                  \n                     Limitations of Use\n                  \n                  DIPRIVAN is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations [see Pediatric Use (8.4)]. \n                  Safety, effectiveness and dosing guidelines for DIPRIVAN have not been established for MAC sedation in the pediatric population; therefore, it is not recommended for this use [see Pediatric Use (8.4)]. \n                  \n                  DIPRIVAN is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established [see Pediatric Use (8.4)].",
    "contraindications": "See Full Prescribing Information for detailed dosing instructions.",
    "warningsAndPrecautions": "DIPRIVAN (propofol) injectable emulsion, USP is available as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Product Code\n                              \n                           \n                           \n                              \n                                 Each\n                              \n                           \n                           \n                              \n                                 Unit of Sale\n                              \n                           \n                           \n                              \n                                 Strength\n                              \n                           \n                        \n                        \n                           \n                              PRX260929\n                           \n                           \n                              NDC 63323-269-4320 mL ready-to-use single-dose vial for single patient use only.\n                           \n                           \n                              NDC 63323-269-94Packages of ten.\n                           \n                           \n                              200 mg per 20 mL(10 mg per mL)\n                           \n                        \n                        \n                           \n                              PRX260950\n                           \n                           \n                              NDC 63323-269-4550 mL ready-to-use single-dose vial for single patient use only.\n                           \n                           \n                              NDC 63323-269-59Packages of twenty.\n                           \n                           \n                              500 mg per 50 mL(10 mg per mL)\n                           \n                        \n                        \n                           \n                              PRX260965\n                           \n                           \n                              NDC 63323-269-41100 mL ready-to-use single-dose vial for single patient use only.\n                           \n                           \n                              NDC 63323-269-69Packages of ten.\n                           \n                           \n                              1,000 mg per 100 mL vial(10 mg per mL)\n                           \n                        \n                     \n                  \n                  Store between 4°C to 25°C (40°F to 77°F). Do not freeze. Shake well before use.",
    "adverseReactions": "DIPRIVAN is contraindicated in patients with a known hypersensitivity to propofol or any of DIPRIVAN components.\n                  DIPRIVAN is contraindicated in patients with a history of anaphylaxis to eggs, egg products, soybeans or soy products."
}